Overview
Milton Essex is a med-tech company specializing in allergy diagnostics, offering products such as the SkinSENS™ system and the Allergoscope program. The company conducts research utilizing artificial intelligence, optoelectronics, and thermodynamics to develop innovative medical systems. Additionally, it focuses on creating new medical procedures and strong partnerships to revolutionize healthcare.
Financials
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Stock quotes
- Open
- PLN 0.54
- High
- PLN 0.55
- Low
- PLN 0.51
- Volume
- 16.33K
- Avg. vol.
- 60.31K
- Market cap
- PLN 41.31M
- P/E ratio
- —
- EPS
- -PLN 0.02
- Shares outstanding
- 75.11M
- 52-week
- PLN 0.43 – 0.59
- Dividend yield
- —
- Dividend
- —
- Ex dividend date
- —
- ISIN
- PLMLTNE00013
- Exchange
- NewConnect
Quarterly results
| Period | Revenue | EBIT | Net profit |
|---|---|---|---|
| Q2 2026 | USD 0.00 | USD -89.14k | USD -89.14k |
| Q1 2026 | USD 0.00 | USD -51.86k | USD -51.86k |
| Q4 2025 | — | — | — |
Results for Q3 2026:Nov 16, 2026
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
News
Industry
Bank accounts
Registered as a VAT taxpayer on 2015-09-22. Active
63 1090 1870 0000 0001 4375 2398- 50 1090 1870 0000 0001 3124 0020
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
MSiG notices
| Publication date | Event | |
|---|---|---|
| Nov 17, 2025 | List of claims | |
| Jun 30, 2020 | Shareholders' meeting convened |
Public aid
11 public aid cases recorded, with a total value of $4,712,432.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Nov 13, 2020 | Aid for research and development projects: industrial research Nov 13, 2020 · Dyrektor Narodowego Centrum Badań i Rozwoju | $1.2M$1,229,870 | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Nov 13, 2020 | Aid for research and development projects: experimental development Nov 13, 2020 · Dyrektor Narodowego Centrum Badań i Rozwoju | $528.8K$528,809 | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Sep 21, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts Sep 21, 2020 · Prezes Zakładu Ubezpieczeń Społecznych | $3,653$3,653 | Prezes Zakładu Ubezpieczeń Społecznych |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2020-06-07 | FACE-COV™ - systemowe rozwiązanie do automatycznego monitorowania miejsc publicznych metodą termowizyjną i detekcji markerów zakażenia SARS-COV2 z użyciem sztucznej inteligencji wraz z opcją identyfikacji biometrycznej (tagowanie cyfrowe) spełniające standardy wyrobu medycznego. 2020-06-07 · Program Operacyjny Inteligentny Rozwój | $1.8M$1,784,321 | Program Operacyjny Inteligentny Rozwój | |
| 2018-07-01 | Uzyskanie międzynarodowej ochrony patentowej 1 wynalazku w obszarze MedTech. 2018-07-01 · Program Operacyjny Inteligentny Rozwój | $54,395$54,395 | Program Operacyjny Inteligentny Rozwój | |
| 2015-09-01 | FIRIMAS – Rozwiązanie dla funkcjonalnego obrazowania w podczerwieni skórnej odpowiedzi alergicznej 2015-09-01 · Program Operacyjny Inteligentny Rozwój | $918.6K$918,612 | Program Operacyjny Inteligentny Rozwój |
Tenders
No recorded participation in tenders.
Authorized Representatives
Manner of representation
President of the Management Board acting independently, or two members of the management board acting jointly.
Supervisory board
Beneficial owners
| Person | Rights |
|---|---|
Jacek Bernard Stępień (63)  | Shareholder of a joint-stock company, 38.77% |
Subsidiaries
| Name | Share value | Stake | |
|---|---|---|---|
Sanford Biotechsp. z o.o. | 2,079.96 USD | 100% | |
Milton Medical AiP.S.A. | 1,350.62 USD | 100% |
Competitors
| Name | Revenue | Website | |
|---|---|---|---|
| Stethomesp. z o.o. Revenue: $267,112.27 · stethome.com | $267,112.27 | stethome.com | |
| ChitomedP.S.A. Revenue: $206,587.41 · chitomed.com | $206,587.41 | chitomed.com | |
| UnitedmedP.S.A. Revenue: $79,858.73 · united-med.pl | $79,858.73 | united-med.pl | |
| Smart Labssp. z o.o. Revenue: $32,047.41 · smart-labs.pl | $32,047.41 | smart-labs.pl |
Change history
| Date | Event |
|---|---|
| 2026-06-12 | Share capital change (1,551,767.00 PLN → 7,511,202.60 PLN) |
| 2024-04-16 | Address change (Ul. Jana Pawła Woronicza 31/348, 02-640, Warszawa → Ul. Żołny 42a, 02-815, Warszawa) |
| 2020-08-05 | Share capital change (1,276,767.00 PLN → 1,551,767.00 PLN) |
| 2019-06-14 | Share capital change (1,136,100.00 PLN → 1,276,767.00 PLN) |
| 2018-04-25 | Share capital change (1,040,100.00 PLN → 1,136,100.00 PLN) |
FAQ
Last updated: 2026-07-30